Belite Bio, Inc
NASDAQ:BLTEBiotechnology
+$0.46 today
- Market cap
- $6.08B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
Volume 0.14M
Average 0.17M
Returns on capital
Belite Bio, Inc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-10.1%
avg 7.6%
ROIC
-10.9%
avg -30.8%
ROA
-9.9%
avg -28.5%
Analysis
ROA is currently the strongest return metric at -9.9% versus its period average of -28.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Kelly Kilpatrick | Chief Commercial Officer | — | — | — | — |
Hendrik Scholl | Chief Medical Officer | — | 57 | — | — |
Nathan L. Mata | Chief Scientific Officer | — | 60 | 0 | <0.01% |
Yu-Hsin Lin | Chairman of the Board of Directors & Chief Executive Officer | — | 48 | 187.95K | 0.47% |
Hao-Yuan Chuang | Chief Financial Officer & Director | — | 42 | 180.26K | 0.45% |
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 29, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
175
$40.63M
Net Transaction Value
−$40.63M
Net selling
Most Active
MATA NATHAN L.
103 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 1, 26Oct 1, 2026 | Scholl Hendrik Peter Indirect | Sell | $4K$3,951.38 |
| Oct 1, 26Oct 1, 2026 | Scholl Hendrik Peter Indirect | Sell | $19.9K$19,859.22 |
| Oct 1, 26Oct 1, 2026 | Scholl Hendrik Peter Indirect | Sell | $8.3K$8,321.84 |
| Oct 1, 26Oct 1, 2026 | Scholl Hendrik Peter Indirect | Sell | $32.7K$32,725.00 |
| Oct 1, 26Oct 1, 2026 | Scholl Hendrik Peter Indirect | Sell | $2.4K$2,371.04 |
| Oct 1, 26Oct 1, 2026 | Scholl Hendrik Peter Indirect | Sell | $340$340.04 |
| Oct 1, 26Oct 1, 2026 | Scholl Hendrik Peter Indirect | Sell | $13.1K$13,071.83 |
| Oct 1, 26Oct 1, 2026 | Scholl Hendrik Peter Indirect | Sell | $2K$2,018.54 |
| Sep 8, 26Sep 8, 2026 | Chuang Hao-Yuan Direct | Sell | $507.4K$507,392.31 |
| Sep 8, 26Sep 8, 2026 | Lin Yu-Hsin Direct | Sell | $1.7M$1,727,274.59 |
1–10 of 175
Summary
Insiders reported 0 buys worth $0.00 and 175 sells worth $40.63M over the last 12 months. That adds up to net selling of $40.63M. MATA NATHAN L. was the most active insider with 103 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Belite Bio, Inc compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about BLTE's management, answered from reported figures.
Who manages BLTE?
Belite Bio, Inc (BLTE) lists 5 active executives. The top listed executive is Kelly Kilpatrick, Chief Commercial Officer.
Are BLTE insiders buying or selling?
Recent insider activity shows net selling of $38.82M.
Continue the stock analysis
Jump to another research area for this company.